IDOV-Immune for Advanced Solid Tumors | MicrobiomeTrials← Back to trialsNCT06910657
IDOV-Immune for Advanced Solid Tumors
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2025-08-25Est. Completion: 2027-01-31
Enrollment target: 78 participants Locations- Washington University School of Medicine, St Louis, Missouri, United States
- MD Anderson Cancer Center, Houston, Texas, United States
- South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States
- Westmead Hospital, Westmead, New South Wales, Australia
- The Alfred Hospital, Melbourne, Victoria, Australia
Other microbiome trials you might be interested in
CRC (Colorectal Cancer)
Efficacy and safety of retlirafusp alfa combined with bevacizumab and chemotherapy with or without short-course radiothe…
Wuhan, ChinaEst. completion Jun 30, 2029
Endometrial AdenocarcinomaEndometrial Clear Cell AdenocarcinomaEndometrial Dedifferentiated CarcinomaEndometrial Endometrioid AdenocarcinomaEndometrial Mixed Cell AdenocarcinomaEndometrial Mucinous Adenocarcinoma
Endometrial Undifferentiated Carcinoma
Endometrioid Adenocarcinoma
Recurrent Endometrial Carcinoma
This phase II trial tests whether the combination of nivolumab and ipilimumab is better than nivolumab alone to shrink t…
Birmingham, United StatesEst. completion Jul 30, 2032
Advanced/Metastatic Solid Tumors
This is a multicenter, open-label, multiple-dose, FIH Phase 1a/1b study. Phase 1a adopts an accelerated titration design…
Los Angeles, United StatesEst. completion Jun 2028